Ajanta Pharma

Ajanta Pharma Q1 result: PAT rises 31% to ₹334 cr on strong India, US sales

Ajanta Pharma Ltd on Thursday reported a 31 per cent rise in profit after tax to Rs 334 crore for the first quarter ended June 30. The company had posted a profit after tax (PAT) of Rs 255 crore in the corresponding period of the last fiscal, Ajanta Pharma said in a regulatory filing. Its revenue from operations grew 25 per cent to Rs 1,626 crore in the first quarter against Rs 1,303 crore in the year-ago period, it added. Branded generics revenue in India increased 24 per cent to Rs 509 crore from Rs 409 crore a year ago, the company said. US generic revenue jumped 57 per cent to Rs 487 crore compared to Rs 310 crore in the year-ago period, it noted.

Ajanta Pharma Q4 FY26 results: Net profit rises 18.4% to ₹266.7 crore

Ajanta Pharma Ltd on Tuesday reported a 18.4 per cent rise in consolidated net profit at Rs 266.7 crore in the fourth quarter ended March 31, on the back of strong US generics revenue growth. The company had posted a consolidated net profit of Rs 225.26 crore in the corresponding period previous fiscal, Ajanta Pharma Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 1,421.64 crore as against Rs 1,170.41 crore in the year-ago period, it added. During the quarter branded generics in the markets of India, Asia and Africa clocked a combined revenue of Rs 859 crore as compared to Rs 805 crore in the year-ago period, up 7 per cent. US generic revenue was at Rs 505 crore as compared to Rs 325 crore in the same period a year ago, up 56 per cent, the company said. Total expenses in the fourth quarter were higher at Rs 1,135.96 crore as compared to Rs 919.11 crore in the same period a year ago, the company said. For FY26, consolidated n

Stocks with bullish momentum: IDBI Bank, CIL, Graphite, JSL, Ajanta Pharma

Coal India, IDBI Bank, Jindal Stainless, Ajanta Pharma and Graphite India were seen trading above the higher end of the Bollinger Bands backed by strong volume on charts.

Ajanta Pharma shares up 3% as Biocon tie-up fuels long-term growth optimism

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide opportunity, and growth outlook

Ajanta Pharma to generate healthy margins from Biocon deal: PL Capital

According to PL Capital, Ajanta Pharma's strong franchise will aid in garnering a higher market share for semaglutide

Stocks with price-volume breakout: Ajanta Pharma, JBMA, Manappuram Finance

Ajanta Pharma, JBMA Auto and Manappuram Finance have seen strong price action backed by heavy trading volume in Wednesday's trading session.

Ajanta Pharma hits over 5-month high after partnering with Biocon

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma signs pact with Biocon to sell semaglutide in 26 countries

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Ajanta Pharma sets aside ₹1K crore for acquisitions to plug therapy gaps

Pain management, dermatology, nephrology and gynaecology are emerging as key focus areas

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Ajanta Pharma offers growth potential amid US generic challenges: Nuvama

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

Ajanta Pharma shares gain 3% on Q2FY26 results, dividend update; details

The dividend, the company said, will be paid on or after November 20, 2025

Ajanta Pharma newly rated 'Buy' at PL Capital; 26% upside seen; check TP

The brokerage analysis suggested that branded generics contributed to 74 per cent of Ajanta Pharma's revenue in FY25 and its branded generics business operates with a healthy OPM of 30 per cent

Tariff worries, Sun Pharma Q1 miss: Why are pharma stocks falling today?

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Stocks to buy today: InCred Equities picks 21 stocks to 'Add' for June 2025

Looking for the best stocks to buy today? Incred Equities has released its top stock picks for June 2025, recommending 21 stocks to 'Add' across largecap, midcap, and smallcap segments

Buy, sell? These stocks fell up to 12% post Q4 results. Check strategy here

Indus Towers, Godrej Agrovet, Phoenix Mills, Ajanta Pharma and Star Health stocks dropped up to 12% in intra-day deals on Friday; here are the key levels to track on these 5 stocks.

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Ajanta Pharma Q3 results: Net profit increases 11% to Rs 233 crore

Ajanta Pharma on Thursday said its consolidated profit after tax increased by 11 per cent on-year to Rs 233 crore for the third quarter ended December 31, 2024. The drug firm had reported a profit after tax (PAT) of Rs 210 crore in the October-December period of last fiscal. Revenue from operations stood at Rs 1,146 crore in the third quarter compared to Rs 1,105 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. Shares of the company settled 1.64 per cent higher at Rs 2,670.70 apiece on the BSE.

Ajanta Pharma share price zooms 4% as ex-dividend date looms; details here

The uptick comes ahead of the company's ex-dividend date tomorrow, driven by its recent dividend announcement that promises rewards for eligible shareholders

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.